Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis

Abstract

Silicosis is an occupational lung disease for which no effective therapy exists. We hypothesized that bosutinib, a tyrosine kinase inhibitor, might ameliorate inflammatory responses, attenuate pulmonary fibrosis, and thus improve lung function in experimental silicosis. For this purpose, we investigated the potential efficacy of bosutinib in the treatment of experimental silicosis induced in C57BL/6 mice by intratracheal administration of silica particles. After 15 days, once disease was established, animals were randomly assigned to receive DMSO or bosutinib (1 mg/kg/dose in 0.1 mL 1% DMSO) by oral gavage, twice daily for 14 days. On day 30, lung mechanics and morphometry, total and differential cell count in alveolar septa and granuloma, levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-4, transforming growth factor (TGF)-β, and vascular endothelial growth factor in lung homogenate, M1 and M2 macrophages, total leukocytes, and T cells in BALF, lymph nodes, and thymus, and collagen fiber content in alveolar septa and granuloma were analyzed. In a separate in vitro experiment, RAW264.7 macrophages were exposed to silica particles in the presence or absence of bosutinib. After 24 h, gene expressions of arginase-1, IL-10, IL-12, inducible nitric oxide synthase (iNOS), metalloproteinase (MMP)-9, tissue inhibitor of metalloproteinase (TIMP)-1, and caspase-3 were evaluated. In vivo, in silicotic animals, bosutinib, compared to DMSO, decreased: (1) fraction area of collapsed alveoli, (2) size and number of granulomas, and mononuclear cell granuloma infiltration; (3) IL-1β, TNF-α, IFN-γ, and TGF-β levels in lung homogenates, (4) collagen fiber content in lung parenchyma, and (5) viscoelastic pressure and static lung elastance. Bosutinib also reduced M1 cell counts while increasing M2 macrophage population in both lung parenchyma and granulomas. Total leukocyte, regulatory T, CD4+, and CD8+ cell counts in the lung-draining lymph nodes also decreased with bosutinib therapy without affecting thymus cellularity. In vitro, bosutinib led to a decrease in IL-12 and iNOS and increase in IL-10, arginase-1, MMP-9, and TIMP-1. In conclusion, in the current model of silicosis, bosutinib therapy yielded beneficial effects on lung inflammation and remodeling, therefore resulting in lung mechanics improvement. Bosutinib may hold promise for silicosis; however, further studies are required.

BMS‑345541 inhibits airway inflammation and epithelial‑mesenchymal transition in airway remodeling of asthmatic mice

“…Therefore, BMS-345541 and DMSO were considered safe and non-toxic. This finding was similar to the results of previous studies ( 15 , 38 ).…”

Vitamin D protects against particles‐caused lung injury through induction of autophagy in an Nrf2‐dependent manner

“…The same group demonstrated that shifting to a type‐1 macrophage activation by administration of IL‐12 resulted in NO synthase‐2 (NOS2, iNOS) overexpression and reduction of fibrosis intensity . Moreover, other studies also reported that the modification of M1/M2 balance is critical in the development of particles exposure caused pulmonary disease . Our study only showed that VD treatment could protect against particles‐induced lung injury by decreasing the macrophages' apoptosis and DNA damage, but not investigated the polarization of macrophage with particle exposure.…”

Cobra Venom Factor-induced complement depletion protects against lung ischemia reperfusion injury through alleviating blood-air barrier damage

“…The main function of MMP2 and MMP9 is to degrade and restore the extracellular matrix and maintain the dynamic balance in basement membrane. MMP2 and MMP9 can destroy the basement membrane and promote inflammation, play an important role in reconstruction extracellular matrix in the process of tissues injury 34 . In this study, ICAM-1, MMP2, MMP9 significantly increased and ZO-1 significantly reduced in lung I/R rat animals, pretreatment with CVF can change the expressions of ICAM-1, ZO-1, MMP2, MMP9.…”